杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/01/30 | 1,794 | 1,800 | 1,777 | 1,777 | -14 | -0.8% | 43,400 |
| 2024/01/29 | 1,779 | 1,794 | 1,779 | 1,791 | +12 | +0.7% | 34,000 |
| 2024/01/26 | 1,795 | 1,795 | 1,778 | 1,779 | -20 | -1.1% | 63,100 |
| 2024/01/25 | 1,793 | 1,800 | 1,788 | 1,799 | +4 | +0.2% | 66,700 |
| 2024/01/24 | 1,798 | 1,801 | 1,783 | 1,795 | -16 | -0.9% | 49,800 |
| 2024/01/23 | 1,809 | 1,829 | 1,809 | 1,811 | +10 | +0.6% | 58,700 |
| 2024/01/22 | 1,795 | 1,811 | 1,795 | 1,801 | +6 | +0.3% | 29,800 |
| 2024/01/19 | 1,817 | 1,821 | 1,782 | 1,795 | -31 | -1.7% | 61,400 |
| 2024/01/18 | 1,826 | 1,829 | 1,816 | 1,826 | +7 | +0.4% | 39,800 |
| 2024/01/17 | 1,845 | 1,845 | 1,818 | 1,819 | -12 | -0.7% | 44,700 |
| 2024/01/16 | 1,840 | 1,848 | 1,823 | 1,831 | -9 | -0.5% | 49,500 |
| 2024/01/15 | 1,812 | 1,840 | 1,812 | 1,840 | +28 | +1.5% | 58,000 |
| 2024/01/12 | 1,835 | 1,838 | 1,803 | 1,812 | -15 | -0.8% | 58,800 |
| 2024/01/11 | 1,834 | 1,835 | 1,818 | 1,827 | +1 | +0.1% | 62,800 |
| 2024/01/10 | 1,814 | 1,828 | 1,804 | 1,826 | +20 | +1.1% | 75,700 |
| 2024/01/09 | 1,792 | 1,814 | 1,792 | 1,806 | +13 | +0.7% | 54,100 |
| 2024/01/05 | 1,812 | 1,812 | 1,787 | 1,793 | -19 | -1% | 56,400 |
| 2024/01/04 | 1,779 | 1,812 | 1,754 | 1,812 | +32 | +1.8% | 105,000 |
| 2023/12/29 | 1,777 | 1,785 | 1,769 | 1,780 | +7 | +0.4% | 47,000 |
| 2023/12/28 | 1,765 | 1,776 | 1,763 | 1,773 | ±0 | ±0% | 40,900 |
| 2023/12/27 | 1,757 | 1,774 | 1,753 | 1,773 | +16 | +0.9% | 60,800 |
| 2023/12/26 | 1,760 | 1,764 | 1,746 | 1,757 | +7 | +0.4% | 53,400 |
| 2023/12/25 | 1,796 | 1,796 | 1,750 | 1,750 | -18 | -1% | 59,900 |
| 2023/12/22 | 1,746 | 1,771 | 1,746 | 1,768 | +16 | +0.9% | 66,100 |
| 2023/12/21 | 1,760 | 1,760 | 1,748 | 1,752 | -8 | -0.5% | 68,700 |
| 2023/12/20 | 1,753 | 1,771 | 1,753 | 1,760 | +7 | +0.4% | 77,000 |
| 2023/12/19 | 1,749 | 1,756 | 1,738 | 1,753 | +20 | +1.2% | 83,200 |
| 2023/12/18 | 1,728 | 1,735 | 1,712 | 1,733 | -10 | -0.6% | 57,400 |
| 2023/12/15 | 1,788 | 1,794 | 1,738 | 1,743 | -49 | -2.7% | 98,300 |
| 2023/12/14 | 1,800 | 1,804 | 1,778 | 1,792 | +6 | +0.3% | 88,100 |
| 2023/12/13 | 1,804 | 1,805 | 1,785 | 1,786 | -18 | -1% | 57,500 |
| 2023/12/12 | 1,826 | 1,833 | 1,802 | 1,804 | -22 | -1.2% | 51,100 |
| 2023/12/11 | 1,804 | 1,834 | 1,804 | 1,826 | -4 | -0.2% | 57,900 |
| 2023/12/08 | 1,838 | 1,838 | 1,819 | 1,830 | -5 | -0.3% | 164,400 |
| 2023/12/07 | 1,836 | 1,848 | 1,827 | 1,835 | -18 | -1% | 52,100 |
| 2023/12/06 | 1,837 | 1,858 | 1,833 | 1,853 | +21 | +1.1% | 97,000 |
| 2023/12/05 | 1,827 | 1,848 | 1,823 | 1,832 | -2 | -0.1% | 68,200 |
| 2023/12/04 | 1,831 | 1,838 | 1,811 | 1,834 | -16 | -0.9% | 65,000 |
| 2023/12/01 | 1,828 | 1,850 | 1,828 | 1,850 | +22 | +1.2% | 99,500 |
| 2023/11/30 | 1,823 | 1,831 | 1,810 | 1,828 | +5 | +0.3% | 167,800 |
| 2023/11/29 | 1,837 | 1,839 | 1,822 | 1,823 | -14 | -0.8% | 61,600 |
| 2023/11/28 | 1,811 | 1,839 | 1,797 | 1,837 | +34 | +1.9% | 107,400 |
| 2023/11/27 | 1,823 | 1,823 | 1,794 | 1,803 | -12 | -0.7% | 73,000 |
| 2023/11/24 | 1,820 | 1,830 | 1,813 | 1,815 | +1 | +0.1% | 77,800 |
| 2023/11/22 | 1,787 | 1,814 | 1,787 | 1,814 | +37 | +2.1% | 93,700 |
| 2023/11/21 | 1,785 | 1,787 | 1,769 | 1,777 | -12 | -0.7% | 59,400 |
| 2023/11/20 | 1,817 | 1,817 | 1,787 | 1,789 | -29 | -1.6% | 85,500 |
| 2023/11/17 | 1,770 | 1,818 | 1,770 | 1,818 | +44 | +2.5% | 114,500 |
| 2023/11/16 | 1,804 | 1,810 | 1,772 | 1,774 | -31 | -1.7% | 90,700 |
| 2023/11/15 | 1,816 | 1,821 | 1,791 | 1,805 | +6 | +0.3% | 72,800 |
201～
250
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
